ArticleDrug delivery and translational research2026
Treatment of myocardial infarction via implantation of electroactive alginate/gelatin cardiac patch seeded with mesenchymal stem cells in a rat model.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial infarction (MI) is a leading cause of mortality around the globe. Cardiac patches offer a promising tissue engineering approach to facilitate the natural regeneration of damaged cardiac tissue. In this research, electroactive cardiac patches composed of alginate-gelatin (Alg-Gel) were fabricated using a freeze-drying technique. The scaffolds were subsequently coated with varying concentrations of reduced graphene oxide (rGO) to improve cardiac performance. The samples were thoroughly characterized in terms of their physicochemical, morphological, and biological properties, including morphology, cell viability, and gene expression. Notably, an rGO concentration of 0.3% w/v significantly improved the viability of bone marrow-derived mesenchymal stem cells (BMSCs) and human umbilical vein endothelial cells (HUVECs), while upregulating the expression of Connexin 43 (Conx43), tryptophan transporter 2 (TrpT-2), and actinin 4 (Actn4), all of which are critical for cardiac cell function. To evaluate therapeutic efficacy in vivo, Alg-Gel-rGO scaffolds seeded with BMSCs were implanted into the infarcted area of a rat model of MI. Echocardiographic, histological, and immunohistochemical analyses demonstrated that the prepared patches improved cardiac function, reduced scar thickness, and promoted angiogenesis, thereby supporting cardiac tissue repair. These findings suggest that Alg-Gel-rGO scaffolds hold significant potential for regenerating damaged myocardial tissue and enhancing post-MI recovery, representing a viable strategy in cardiac tissue engineering.
Indexed as
Identifiers
41903101What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.